Antiplatelet Regimen Tailoring after primary Percutaneous Coronary Intervention (ART-PCI): a single centre longitudinal cohort prospective trial

Clinical Centre of Serbia (Serbia)0 个研究点目标入组 1,700 人开始时间: 2010年2月18日最近更新: 2015年1月13日

适应症

试验速览

暂无简介。

•1. ST-elevation myocardial infection (STEMI) patients undergoing primary PCI in our institution
•2. Both genders, aged greater than 18 years
•3. Platelet residual aggregation (PRA) assessed 24 hours after the loading with clopidogrel 600 mg
•4. Control group: 1000 patients enrolled in the RISK-PCI trial (see http://www.controlled-trials.com/ISRCTN83474650) in our centre from February 1st, 2006 till June 1st, 2008, who did not have platelet function assays
•Low responders to clopidogrel will be subjected to ART if there is no exclusion criteria for ART.

•1. Not alive until 24 hours from clopidogrel loading 600 mg
•2. Aged greater than 75 years
•3. Percutaneous balloon angioplasty (POBA) without stenting
•4. Failed pPCI
•5. Active bleeding in hospital
•6. Coronary dissection with pericardial collection
•7. Haemoglobin (Hb) less than 80 g/dL needing transfusion in hospital
•8. Simultaneous treatment with oral anticoagulants
•9. Candidates for urgent bypass surgery
•10. Low basal thrombin receptor activating peptide (TRAP) value (less than 500 AU/minute)
•11. Hystory of recent bleeding from ulcer
•12. Thrombocyte count less than 100,000/ml
•13. Drug non-compliance
•14. Withdrawal of consent

发起方

Clinical Centre of Serbia (Serbia)